|Articles|June 1, 2003
- BioPharm International-06-02-2003
- Volume 2003 Supplement
- Issue 1
Part 2: Red Blood Cells and Platelets
Author(s)Gail Sofer
by Gail Sofer, BioReliance
Advertisement
Articles in this issue
over 22 years ago
Part 1: Skin, Bone, and Cellsover 22 years ago
BioPharm International's Virus Inactivation Series: A Prefaceover 22 years ago
Part 4: Culture Media, Biotechnology Products, and Vaccinesover 22 years ago
Inactivation of Viruses: An Introduction to the Seriesover 22 years ago
Part 6: Inactivation Methods Grouped by Virusover 22 years ago
Part 5: DisinfectionNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4